RxDoctor Payments Data

Jennifer Fishel, OD

Optometrist · Bristol, TNNPI 1770584567

Payments from drug & device makers

$2,134in general payments, 2019–2025

Across 68 payments — averaging $31.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$347
  • Alcon$284
  • Harrow Eye, LLC$241
  • Oyster Point Pharma, Inc.$237
  • Maculogix, Inc.$153
  • AbbVie$125
  • plus $747 from 15 others

What the payments were for

  • Speaking & faculty fees$502%
  • Food & beverage$2,08498%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,134 in reported general payments places this provider in the 75th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$117,168
Medicare patients
656
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine83$72,611
XiidraLifitegrast13$10,272
Alphagan PBrimonidine Tartrate14$7,135
Cyclosporine15$6,566
LumiganBimatoprost19$6,264
Latanoprost467$3,548
Travoprost19$2,486
Brimonidine Tartrate67$2,419
Prednisolone Acetate58$2,215
MoxifloxacinMoxifloxacin Hcl62$1,675
ErythromycinErythromycin Base128$1,433
Doxycycline Monohydrate30$857
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$617
Timolol Maleate42$391
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat41$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan$125$86,010116 claims
Bausch & Lomb Americas Inc.Xiidra$347$10,27213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →